Business Context and Reporting Period
This Form 8-K Current Report was filed by GoodRx Holdings, Inc. on April 23, 2026. The filing addresses Item 5.02 regarding the appointment of a new Chief Accounting Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of Thomas Chan as Chief Accounting Officer, effective immediately on April 23, 2026. Mr. Chan was previously the Vice President, Corporate Controller. His compensation package includes:
- Base Salary: Increased to $310,000 annually.
- Target Bonus: 40% of base salary.
- Restricted Stock Units (RSU): Aggregate value of $131,250, vesting ratably over 12 quarters starting August 15, 2026.
- Performance-Based RSUs (PSU): Aggregate value of $43,750, vesting in three equal installments contingent on performance goals.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. It notes that there are no transactions in which the Company is a party and in which Mr. Chan has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the grant date and share count for the RSU and PSU awards based on the closing share price over the 30 days preceding the grant.
- Confirm the vesting schedule commencement date of August 15, 2026, for the RSU award.
- Review the specific performance goals attached to the PSU award in future filings or proxy statements.
- Check for any subsequent filings regarding the departure of the previous Chief Accounting Officer.